C4 Therapeutics vs Kymera Therapeutics
Kymera Therapeutics reported revenue of $39 million in fiscal 2025, about the same as C4 Therapeutics' $36 million in fiscal 2025. C4 Therapeutics' revenue grew 1.0% in its latest year, and Kymera Therapeutics' fell 16.7%. C4 Therapeutics had an operating margin of -320.5%, against -891.1% at Kymera Therapeutics. Free cash flow was −$99 million at C4 Therapeutics and −$234 million at Kymera Therapeutics.
Side by side
| C4 Therapeutics | Kymera Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $36M | $39M |
| Revenue growth | 1.0% | −16.7% |
| Revenue growth a year, last 5 years | — | 2.9% |
| Gross margin | — | 0.0% |
| Operating margin | −320.5% | −891.1% |
| Net margin | −292.1% | −794.0% |
| Free cash flow | −$99M | −$234M |
| Free cash flow margin | −276.2% | −597.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.5% | 12.6% |
| Last close | $2.44 | $119.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $22,200 | bought $172.5 million, sold $461.2 million |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
C4 TherapeuticsKymera Therapeutics
Operating margin
Percent of revenue
C4 TherapeuticsKymera Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
C4 TherapeuticsKymera Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the C4 Therapeutics and Kymera Therapeutics pages.